thioctic acid has been researched along with Parkinson Disease in 18 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aging risk factor for Parkinson's disease is described in terms of specific disease markers including mitochondrial and gene dysfunctions relevant to energy metabolism." | 2.50 | Management of the aging risk factor for Parkinson's disease. ( Phillipson, OT, 2014) |
| "Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD." | 2.42 | Bioenergetic approaches for neuroprotection in Parkinson's disease. ( Beal, MF, 2003) |
| "In a model of early-stage Parkinson's disease induced by a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Wistar rats, a neuroprotective effect of a new derivative of carnosine and α-lipoic acid (C/LA nanomicellar complex) was demonstrated." | 1.48 | Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease. ( Berezhnoy, DS; Fedorova, TN; Kulikova, OI; Lopachev, AV; Orlova, VS; Stvolinsky, SL, 2018) |
| " Chronic use of (-)-15 reduced L-DOPA-induced dyskinesia (LID) without attenuating the antiparkinsonian effect." | 1.37 | Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. ( Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S, 2011) |
| " Combination of α-lipoic acid efficiently halting deleterious toxic effects of L-dopa, revealed normalization of catalepsy score in addition to amelioration of neurochemical parameters and apparent preservation of striatal ultrastructure integrity, indicating benefit of both symptomatic and neuroprotective therapy." | 1.37 | Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity. ( Abdin, AA; Sarhan, NI, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, J | 1 |
| Wang, M | 1 |
| Zhao, Y | 1 |
| Zhang, Y | 2 |
| Gao, Y | 1 |
| Zhang, X | 2 |
| Yang, G | 1 |
| Zheng, Q | 1 |
| Ma, P | 1 |
| Yang, P | 1 |
| Zhai, S | 2 |
| He, M | 1 |
| Tu, Q | 1 |
| Jiao, L | 2 |
| Ye, L | 1 |
| Feng, Z | 1 |
| Zhang, C | 2 |
| Zhao, H | 1 |
| Zhao, X | 1 |
| Liu, L | 1 |
| Zhang, H | 3 |
| Xuan, M | 1 |
| Guo, Z | 1 |
| Wang, H | 1 |
| Liu, C | 1 |
| Zhou, B | 1 |
| Wen, M | 1 |
| Lin, X | 1 |
| Chen, YH | 1 |
| Gou, Y | 1 |
| Li, Y | 1 |
| Li, HW | 1 |
| Tang, L | 1 |
| Zhang, SF | 1 |
| Xie, CL | 1 |
| Lin, JY | 1 |
| Wang, MH | 1 |
| Wang, XJ | 1 |
| Liu, ZG | 1 |
| Cai, T | 1 |
| Wei, C | 1 |
| Tai, S | 1 |
| Kulikova, OI | 1 |
| Berezhnoy, DS | 1 |
| Stvolinsky, SL | 1 |
| Lopachev, AV | 1 |
| Orlova, VS | 1 |
| Fedorova, TN | 1 |
| Phillipson, OT | 1 |
| Cortesi, R | 1 |
| Esposito, E | 1 |
| Drechsler, M | 1 |
| Pavoni, G | 1 |
| Cacciatore, I | 1 |
| Sguizzato, M | 1 |
| Di Stefano, A | 1 |
| Lee, SH | 1 |
| Kim, MJ | 1 |
| Kim, BJ | 1 |
| Kim, SR | 1 |
| Chun, S | 1 |
| Ryu, JS | 1 |
| Kim, GS | 1 |
| Lee, MC | 1 |
| Koh, JM | 1 |
| Chung, SJ | 1 |
| Jia, H | 1 |
| Liu, J | 3 |
| Ao, N | 1 |
| Yan, B | 1 |
| Shen, W | 1 |
| Wang, X | 1 |
| Li, X | 1 |
| Luo, C | 1 |
| De Araújo, DP | 1 |
| Lobato, Rde F | 1 |
| Cavalcanti, JR | 1 |
| Sampaio, LR | 1 |
| Araújo, PV | 1 |
| Silva, MC | 1 |
| Neves, KR | 1 |
| Fonteles, MM | 1 |
| Sousa, FC | 1 |
| Vasconcelos, SM | 1 |
| Ye, N | 1 |
| Zhou, S | 1 |
| Guo, L | 1 |
| Zheng, L | 1 |
| Liu, Z | 1 |
| Gao, B | 1 |
| Zhen, X | 1 |
| Zhang, A | 1 |
| Abdin, AA | 1 |
| Sarhan, NI | 1 |
| Zaitone, SA | 1 |
| Abo-Elmatty, DM | 1 |
| Shaalan, AA | 1 |
| Zahid, M | 1 |
| Saeed, M | 1 |
| Yang, L | 1 |
| Beseler, C | 1 |
| Rogan, E | 1 |
| Cavalieri, EL | 1 |
| Bharat, S | 1 |
| Cochran, BC | 1 |
| Hsu, M | 1 |
| Ames, BN | 1 |
| Andersen, JK | 1 |
| Beal, MF | 1 |
3 reviews available for thioctic acid and Parkinson Disease
| Article | Year |
|---|---|
Management of the aging risk factor for Parkinson's disease.
Topics: Acetylcarnitine; Adenosine Triphosphate; Aging; alpha-Synuclein; Antioxidant Response Elements; Carb | 2014 |
The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: a review.
Topics: Animals; Antioxidants; Apoptosis; Disease Progression; Humans; Nerve Degeneration; Oxidative Stress; | 2011 |
Bioenergetic approaches for neuroprotection in Parkinson's disease.
Topics: Acetylcarnitine; Coenzymes; Creatine; Energy Metabolism; Free Radicals; Ginkgo biloba; Humans; Mitoc | 2003 |
1 trial available for thioctic acid and Parkinson Disease
| Article | Year |
|---|---|
Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.
Topics: Absorptiometry, Photon; Aged; Analysis of Variance; Anthropometry; Antioxidants; Bone Demineralizati | 2010 |
14 other studies available for thioctic acid and Parkinson Disease
| Article | Year |
|---|---|
Alpha-lipoic acid improved motor function in MPTP-induced Parkinsonian mice by reducing neuroinflammation in the nigral and spinal cord.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Alpha lipoic acid ameliorates motor deficits by inhibiting ferroptosis in Parkinson's disease.
Topics: Animals; Iron; Iron Chelating Agents; Neurodegenerative Diseases; NF-E2-Related Factor 2; Parkinson | 2023 |
Neurochemical effects of the R form of α-lipoic acid and its neuroprotective mechanism in cellular models of Parkinson's disease.
Topics: Cell Line, Tumor; Cell Survival; Gene Expression Regulation; Humans; Mitochondria; Neuroprotective A | 2017 |
Alpha Lipoamide Ameliorates Motor Deficits and Mitochondrial Dynamics in the Parkinson's Disease Model Induced by 6-Hydroxydopamine.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apomorphine; Cell Death; Disease Models, Animal; Dopa | 2018 |
Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress.
Topics: Animals; Antioxidants; Caspase 3; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Ind | 2018 |
[Mechanism of α-lipoic acid promoting iron efflux in substantia nigra cells of Parkinson's disease rats].
Topics: Animals; Cation Transport Proteins; Iron; Iron Regulatory Protein 2; Male; Parkinson Disease; Rats; | 2018 |
Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Carnosine; Dopamine; Homovanillic Acid | 2018 |
L-dopa co-drugs in nanostructured lipid carriers: A comparative study.
Topics: Caffeic Acids; Drug Carriers; Drug Liberation; Half-Life; Humans; Kinetics; Levodopa; Lipids; Micros | 2017 |
Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease.
Topics: Acetylcarnitine; alpha-Synuclein; Antioxidants; Drug Synergism; Humans; Mitochondria; Oxidation-Redu | 2010 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Criceti | 2011 |
Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Topics: Animals; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Levodopa; Mitochondria; Neurons; N | 2011 |
Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.
Topics: Acetylcarnitine; Adenosine Triphosphate; Animals; Antioxidants; Dietary Supplements; Dopamine; Dopam | 2012 |
Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease.
Topics: Acetylcysteine; Antioxidants; Benzoquinones; DNA Adducts; Dopamine; Humans; Hydrogen-Ion Concentrati | 2011 |
Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy.
Topics: Animals; Antioxidants; Buthionine Sulfoximine; Cytoplasm; Glutamate-Cysteine Ligase; Glutathione; Mi | 2002 |